Glibenclamide
Specifications :
| Common/INN Name: Glibenclamide or Glyburide | ||||||||||||||
| IUPAC Name : 5-chloro-N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide | ||||||||||||||
| CAS No : 10238-21-8 | ||||||||||||||
| Molecular Formula : C 23 H 28 ClN 3 O5 S | ||||||||||||||
| Molecular Mass : 494.004 gm/mol | ||||||||||||||
| Chemical Structure: : | ||||||||||||||
| Pharmacopeial Grade : IP/BP/EP/USP | ||||||||||||||
| A.P.I. Products List | |||||
| S.No. | TEST | SPECIFICATION | |||
| 1 | Appearance | White or almost white, crystalline powder | |||
| 2 | Solubility | Practically insoluble in water, sparingly soluble in Methylene chloride, slightly soluble in alcohol and in methanol. | |||
| 3 | |||||
| Identification | |||||
| (A) Melting Point | 169 °C to 174 °C. | ||||
| (B) By UV | The solution shows an absorption maximum at 300 nm and a less intense maximum at 275 nm. The specific Absorbance at the maxima are 61 to 65 and 27 to 32, |
||||
| (C) By TLC | The principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with the reference solution. | ||||
| (D)By Colour Development | In resulting test solution should be colorless and shows blue fluorescence in ultraviolet light at 365 nm. | ||||
| 4 | Related substances (By HPLC) | - | |||
| 4.1 | Impurity A | NMT 0.5 per cent | |||
| 4.2 | Impurity B | NMT 0.5 per cent | |||
| 4.3 | Any Other Impurity: | NMT 0.2 per cent | |||
| 4.4 | Unknown Impurity-1 | NMT 0.1 per cent | |||
| 4.5 | Unknown Impurity-2 | NMT 0.1 per cent | |||
| 4.6 | Total Of Other Impurities: | NMT 0.5 per cent | |||
| 5 | Heavy metals | NMT 20 ppm | |||
| 6 | Loss on drying | NMT 1.0 % w/w | |||
| 7 | Sulphated ash | NMT 0.1 % w/w | |||
| 8 | Assay | Between 99.0 per cent to 101.0 per cent (dried substance) | |||
Packing :25 Kg HDPE or Fiber Drums/ Custom Packing Available
Stability : Stable at ambient temperature
Usage: : Glibenclamide (INN), also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). As of 2007, it is one of only two oral antidiabetics in the World Health Organization Model List of Essential Medicines (the other being metformin). As of 2003, in the United States, it was the most popular sulfonylurea.
Source:- http://www.elixirpharma.in/Glibenclamide.html
No comments:
Post a Comment
Note: only a member of this blog may post a comment.